Search research articles
Contact Us
Filters
Showing results (31-40 of 49) with videos related to
Page
of 5
Sort By:
Prostate Cancer and Prostatic Diseases
|
February 11, 2010
Does pre-existing diabetes affect prostate cancer prognosis? A systematic review
C F Snyder, K B Stein, B B Barone, et al.
Clinical Pharmacology and Therapeutics
|
January 10, 2008
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements
A C Hooker, A J Ten Tije, M A Carducci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
M J Morris, M A Eisenberger, R Pili, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2013
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer
A J Armstrong, M Häggman, W M Stadler, et al.
Cancer Chemotherapy and Pharmacology
|
November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors
E I Heath, S O'Reilly, R Humphrey, et al.
Prostate Cancer and Prostatic Diseases
|
June 13, 2012
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer
C J Paller, X Ye, P J Wozniak, et al.
Leukemia
|
June 11, 2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K W Pratz, E Cho, M J Levis, et al.
Clinical Pharmacology and Therapeutics
|
May 30, 2008
Pharmacogenetic pathway analysis of docetaxel elimination
S D Baker, J Verweij, G A Cusatis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 15, 2021
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
A A Hamid, H-C Huang, V Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
A Tripathi, Y Chen, D F Jarrard, et al.
Page
of 5
Search research articles
Search
Showing results (31-40 of 49) with videos related to
Sort By:
Page
of 5
Prostate Cancer and Prostatic Diseases
|
February 11, 2010
Does pre-existing diabetes affect prostate cancer prognosis? A systematic review
C F Snyder, K B Stein, B B Barone, et al.
Clinical Pharmacology and Therapeutics
|
January 10, 2008
Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P4503A activity measurements
A C Hooker, A J Ten Tije, M A Carducci, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
May 4, 2012
A phase I/IIA study of AGS-PSCA for castration-resistant prostate cancer
M J Morris, M A Eisenberger, R Pili, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 21, 2013
Long-term survival and biomarker correlates of tasquinimod efficacy in a multicenter randomized study of men with minimally symptomatic metastatic castration-resistant prostate cancer
A J Armstrong, M Häggman, W M Stadler, et al.
Cancer Chemotherapy and Pharmacology
|
November 17, 2001
Phase I trial of the matrix metalloproteinase inhibitor BAY12-9566 in patients with advanced solid tumors
E I Heath, S O'Reilly, R Humphrey, et al.
Prostate Cancer and Prostatic Diseases
|
June 13, 2012
A randomized phase II study of pomegranate extract for men with rising PSA following initial therapy for localized prostate cancer
C J Paller, X Ye, P J Wozniak, et al.
Leukemia
|
June 11, 2010
A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemias
K W Pratz, E Cho, M J Levis, et al.
Clinical Pharmacology and Therapeutics
|
May 30, 2008
Pharmacogenetic pathway analysis of docetaxel elimination
S D Baker, J Verweij, G A Cusatis, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 15, 2021
Transcriptional profiling of primary prostate tumor in metastatic hormone-sensitive prostate cancer and association with clinical outcomes: correlative analysis of the E3805 CHAARTED trial
A A Hamid, H-C Huang, V Wang, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
August 25, 2025
Ten-year survival rates by PSA nadir in patients with metastatic hormone-sensitive prostate cancer: long-term survival analysis from the ECOG-ACRIN 3805 (CHAARTED) trial
A Tripathi, Y Chen, D F Jarrard, et al.
Page
of 5